Our Company Features
Most advanced adhesion and delivery system
Proprietary patch technology optimizes drug delivery through the skin.
Anti-inflammatory oral solution delivers individualized dosing
Precision dosing in high risk patients.
The only liquid ready-to-use analgesic formulated in a proprietary delivery system
Delivers fast and long lasting migraine relief.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and becoming the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products that maximize quality of life.
About Us
Leader in non-opioid pain management products
Scilex Holding Company (Nasdaq: SCLX) is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
Product Portfolio
OPTIMIZE QUALITY OF LIFE THROUGH PHARMACEUTICALS
Testimonals
Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion
Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose
Corporate Presentation
Scilex Holding Company Corporate Presentation
Download here »
October 16, 2024
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
Read More »October 16, 2024
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion
Read More »Do you have any questions? Lets talk!
650-516-4310